Loading…
Strategic Analysis
To win this competitive two-stage topic, proposals must present a robust, statistically powered early-stage clinical trial (Phase I/IIa) evaluating an innovative intervention for a targeted neurodegenerative condition, tightly coupled with deep mechanistic multi-omics/imaging profiling and real-world digital health monitoring. Success requires embedding end-to-end regulatory alignment (EMA/national authorities) and co-creation with patient advocacy groups, underpinned by existing pan-European research infrastructures such as ECRIN, EBRAINS, and BBMRI-ERIC.
Everything the call asks for, seen from the call's point of view. Each line shows what answers it, and which partner carries it.
This matrix lists everything the call asks for: outcomes, impacts, scope, the requirements buried in the call text, and policy alignment. Sign up free and GrantForge tracks each line against the concept you build.
| Requirement | Covered by | Carried | Status |
|---|---|---|---|
| Scope activities | |||
| SC1Perform rigorous early-stage [3] clinical trials into the safety and efficacy of the innovative interventions and their mode of administration, ensuring adequate cohorts/sample sizes with adequate representation of the patient population, including in terms of age, sex and ethnicity. | · | · | Sign up to track |
| SC2Through the clinical trials and to the extent possible of additional studies, gain further insight into the potentially novel mechanism(s) of action of the innovative therapies and complementary approaches. This could entail analyses of imaging (e.g. MRI, ultrasound, nuclear imaging), as well as physiological, molecular, biochemical or omics signatures revealing potential perturbations prior to the intervention and recovery/improvement thereafter, and it could lead to the development of surrogate endpoints. This insight should open the path to more personalised interventions and approaches. | · | · | Sign up to track |
| SC3Use and/or develop technologies, including digital ones (e.g. (generative) Artificial Intelligence - AI [4] , wearable technologies) to help implement and monitor the long-term efficacy of the intervention(s), as well as manage the disorder and/or monitor their progression (e.g. with unobtrusive technologies suitable for patient monitoring at home and in real-world conditions), whilst also ensuring they are bias-free, inclusive, and ethically sound. | · | · | Sign up to track |
| SC4Utilise existing data, biobanks, registries and/or cohorts, together with the generation of new data that should be managed in line with the FAIR principles. | · | · | Sign up to track |
| SC5Engage all relevant stakeholders (especially patients and patients’ representatives for the disease, caregivers, clinicians, counsellors, regulators, etc.) to design end-user optimised interventions, applying gender-sensitive and intersectional approaches. | · | · | Sign up to track |
| SC6Advance research by leveraging already existing and emerging state-of-the-art research infrastructures (e.g. EuroBioImaging [5] , European Genomic Data Infrastructure [6] , ECRIN [7] , EATRIS [8] , EBRAINS [9] , BBMRI [10] , etc.), as well as results stemming from EU-supported research projects, where applicable [11] . | · | · | Sign up to track |
| SC7Engage with national public health authorities and regulators to ensure a robust development pathway and further uptake of the intervention. | · | · | Sign up to track |
| Expected outcomes | |||
| EO1The scientific and clinical communities make effective use of state-of-the-art knowledge, data, technologies, tools, methods, best practices, and trainings to underpin and complement the development of innovative interventions aimed at more effective treatments for neurodegenerative diseases. | · | · | Sign up to track |
| EO2The scientific and clinical communities benefit from the exchange of data, knowledge and best practices, thereby strengthening their collaboration in the EU, the Associated Countries and beyond. | · | · | Sign up to track |
| EO3The scientific and clinical communities make wide use of relevant databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR [1] principles, thereby encouraging further use of the data. | · | · | Sign up to track |
| EO4Policymakers, funders, scientific and clinical communities, patient organisations, regulators, and other relevant bodies are informed of the research advances made and the requirements for a widespread implementation of the innovative therapeutic interventions and complementary approaches. | · | · | Sign up to track |
| EO5Patients and caregivers are constructively engaged with the research, ensuring that their needs are catered for, with the aim of tangibly benefitting from the interventions. | · | · | Sign up to track |
| Other requirements | |||
| REQ1Contribution of social sciences and humanities (SSH) disciplinesThe topic requires the effective contribution of SSH disciplines and the involvement of SSH experts and institutions to enhance the societal impact of the research activities. | · | · | Sign up to track |
| REQ2Gender-sensitive and intersectional approaches in stakeholder engagementProposals should engage all relevant stakeholders (patients, caregivers, clinicians, regulators) applying gender-sensitive and intersectional approaches to design end-user optimised interventions. | · | · | Sign up to track |
| REQ3Synergies with the European Partnership for Brain HealthFunded projects should liaise with the co-funded European Partnership for Brain Health covered by topic HORIZON-HLTH-2025-02-DISEASE-01. | · | · | Sign up to track |
| REQ4Leveraging pan-European research infrastructures and EU projectsProposals should leverage existing and emerging research infrastructures (such as EuroBioImaging, European Genomic Data Infrastructure, ECRIN, EATRIS, EBRAINS, BBMRI) and results from EU-supported research projects. | · | · | Sign up to track |
| REQ5Inter-project networking and joint activitiesAll funded projects are strongly encouraged to participate in networking and joint activities, and proposals must include a budget for attendance to regular joint meetings. | · | · | Sign up to track |
| REQ6FAIR data management and data sharingExisting data, biobanks, registries, and cohorts should be utilised alongside new data that must be managed and shared in line with FAIR principles. | · | · | Sign up to track |
| REQ7Engagement with national public health authorities and regulatorsProposals should engage with national public health authorities and regulators to ensure a robust development pathway and further uptake of the intervention. | · | · | Sign up to track |
| REQ8Mandatory use of Copernicus and/or Galileo/EGNOS earth observation servicesIf projects use satellite-based earth observation, positioning, navigation, or timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS. | · | · | Sign up to track |
| REQ9Ethical and bias-free digital technologies and AITechnologies developed or used, including generative AI and wearables, must be bias-free, inclusive, and ethically sound. | · | · | Sign up to track |
| Expected impacts | |||
| No expected impacts in this call. | |||
| Underlying policies | |||
| POL1regulation (ec) no 141/2000 orphan medicinal productsRegulation (EC) No 141/2000 sets out the EU framework to encourage the research, development, and marketing of orphan medicinal products for rare diseases affecting no more than 5 in 10,000 people in the EU. It establishes incentives such as protocol assistance, fee reductions for regulatory procedures, and a 10-year market exclusivity period upon marketing authorization. | · | · | Sign up to track |
The binding rules of this call. Items marked auto are verified by GrantForge from the call and the template. The others are yours to confirm.
LMIC entities auto-eligible
Low/middle-income country entities are automatically eligible for funding.
Page limit Stage 1
Part B Section 1+2+3 combined is typically capped at 10 pages at Stage 1. Pages exceeding the limit are invisible to evaluators.
Consortium continuity
The consortium declared at Stage 1 is expected to submit Stage 2. Substantial changes must be justified.
EU space data infrastructures
If the project uses satellite-based Earth observation, positioning, navigation or timing data/services, beneficiaries must use Copernicus and/or Galileo/EGNOS.
Civil applications only
Exclusive military or dual-use applications are excluded.
US entities eligible for funding
Any legal entity established in the United States of America is eligible to receive Union funding in recognition of the opening of the US National Institutes of Health's programmes to European researchers.
5 key insights you must internalise before writing. Each is grounded in the call text and tells you what evaluators will actually look for. Share these with your consortium before drafting.
Stage 1 proposals are subject to strict blind evaluation rules. Any mention of consortium member names, institutional acronyms, logos, or recognizable personnel in Part B will lead to immediate disqualification before any scoring occurs. Applicants must meticulously anonymize their 10-page pre-proposal while still proving the methodological rigor of their clinical trial.
Source: Evaluation_pre_award
Despite general health policy frameworks regarding orphan drugs, this specific call explicitly excludes rare neurodegenerative diseases (defined as affecting fewer than 1 in 2,000 people in the EU). Proposals targeting orphan indications will be deemed out of scope; applicants must ensure their target condition meets the prevalence threshold for a broader societal burden.
Source: Scope
A purely pharmacological clinical trial will not meet the scope requirements. The therapeutic solution based on an active substance must be combined or complemented with a multidisciplinary approach, such as lifestyle changes, cognitive training, or rehabilitation therapies. This combined intervention is a core expectation to improve quality of life and reduce societal impact.
Source: Scope
Under a specific reciprocity provision with the US National Institutes of Health, any legal entity established in the United States is fully eligible to receive direct Union funding. Consortia can strategically integrate top-tier US clinical trial sites, digital health providers, or research institutions without the usual third-country funding barriers.
Source: Eligibility rules
Evaluators will heavily penalize isolated clinical trials. Success requires explicit synergistic integration with established European research infrastructures (e.g., ECRIN, EBRAINS, BBMRI) for data governance. Furthermore, proposals must document early dialogue mechanisms with health regulatory agencies, such as EMA Scientific Advice, to de-risk late-stage translation.
Source: Evaluation_pre_award
Specific requirements
Page limit Stage 1
Part B Section 1+2+3 combined is typically capped at 10 pages at Stage 1. Pages exceeding the limit are invisible to evaluators.
Consortium continuity
The consortium declared at Stage 1 is expected to submit Stage 2. Substantial changes must be justified.
EU space data infrastructures
If the project uses satellite-based Earth observation, positioning, navigation or timing data/services, beneficiaries must use Copernicus and/or Galileo/EGNOS.
Civil applications only
Exclusive military or dual-use applications are excluded.
US entities eligible for funding
Any legal entity established in the United States of America is eligible to receive Union funding in recognition of the opening of the US National Institutes of Health's programmes to European researchers.
">
Applicants submitting a proposal for a blind evaluation (see General Annex F) must not disclose their organisation names, acronyms, logos nor names of personnel in the proposal abstract and Part B of their first-stage application (see General Annex E).
Admissibility conditions are described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout are described in Part B of the Application Form available in the Submission System.
Eligible countries are described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).
Subject to restrictions for the protection of European communication networks.
Other eligibility conditions are described in Annex B of the Work Programme General Annexes.
Financial and operational capacity and exclusion are described in Annex C of the Work Programme General Annexes.
The first-stage proposals of this topic will be evaluated blindly.
Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.
For the first stage, the thresholds for each criterion will be 4 (Excellence) and 4 (Impact). The overall threshold applying to the sum of the two individual scores will be set at a level that ensures the total requested budget of proposals admitted to stage 2 is as close as possible to four times the available budget, and not less than three and a half times the available budget.
For the second stage, the thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.
Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual.
Indicative timeline for evaluation and grant agreement are described in Annex F of the Work Programme General Annexes.
The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.
Legal and financial set-up of the grants are described in Annex G of the Work Programme General Annexes.
Specific conditions are described in the specific topic of the Work Programme.
Application and evaluation form templates
Standard application form (HE RIA IA Stage 1 BLIND) - the application form specific to this call is available in the Submission System
Standard application form (HE RIA, IA) - the application form specific to this call is available in the Submission System
Standard evaluation form (HE RIA, IA and CSA Stage 1 BLIND) - will be used with the necessary adaptations
Standard evaluation form (HE RIA, IA) - will be used with the necessary adaptations
Guidance
Model Grant Agreement (MGA)
Call-specific instructions
Information on clinical studies (HE)
HE Main Work Programme 2026-2027 – 1. General Introduction
HE Main Work Programme 2026-2027 – 4. Health
HE Main Work Programme 2026-2027 – 15. General Annexes
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Decision authorising the use of lump sum contributions under the Horizon Europe Programme
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Evaluators are bound by strict blind evaluation rules in Stage 1: any mention of consortium member names, acronyms, host institutions, or recognizable personnel in Part B will lead to immediate proposal disqualification. With a 10-page limit and high threshold (minimum 4/5 each for Excellence and Impact, with the competitive cutoff typically higher to meet the 3.5x-4x budget capacity), evaluators will prioritize:
TRL 2 → 6
Based on programme defaults
Perform rigorous early-stage [3] clinical trials into the safety and efficacy of the innovative interventions and their mode of administration, ensuring adequate cohorts/sample sizes with adequate representation of the patient population, including in terms of age, sex and ethnicity.
Through the clinical trials and to the extent possible of additional studies, gain further insight into the potentially novel mechanism(s) of action of the innovative therapies and complementary approaches. This could entail analyses of imaging (e.g. MRI, ultrasound, nuclear imaging), as well as physiological, molecular, biochemical or omics signatures revealing potential perturbations prior to the intervention and recovery/improvement thereafter, and it could lead to the development of surrogate endpoints. This insight should open the path to more personalised interventions and approaches.
Use and/or develop technologies, including digital ones (e.g. (generative) Artificial Intelligence - AI [4] , wearable technologies) to help implement and monitor the long-term efficacy of the intervention(s), as well as manage the disorder and/or monitor their progression (e.g. with unobtrusive technologies suitable for patient monitoring at home and in real-world conditions), whilst also ensuring they are bias-free, inclusive, and ethically sound.
Utilise existing data, biobanks, registries and/or cohorts, together with the generation of new data that should be managed in line with the FAIR principles.
Engage all relevant stakeholders (especially patients and patients’ representatives for the disease, caregivers, clinicians, counsellors, regulators, etc.) to design end-user optimised interventions, applying gender-sensitive and intersectional approaches.
Advance research by leveraging already existing and emerging state-of-the-art research infrastructures (e.g. EuroBioImaging [5] , European Genomic Data Infrastructure [6] , ECRIN [7] , EATRIS [8] , EBRAINS [9] , BBMRI [10] , etc.), as well as results stemming from EU-supported research projects, where applicable [11] .
Engage with national public health authorities and regulators to ensure a robust development pathway and further uptake of the intervention.
The scientific and clinical communities make effective use of state-of-the-art knowledge, data, technologies, tools, methods, best practices, and trainings to underpin and complement the development of innovative interventions aimed at more effective treatments for neurodegenerative diseases.
The scientific and clinical communities benefit from the exchange of data, knowledge and best practices, thereby strengthening their collaboration in the EU, the Associated Countries and beyond.
The scientific and clinical communities make wide use of relevant databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR [1] principles, thereby encouraging further use of the data.
Policymakers, funders, scientific and clinical communities, patient organisations, regulators, and other relevant bodies are informed of the research advances made and the requirements for a widespread implementation of the innovative therapeutic interventions and complementary approaches.
Patients and caregivers are constructively engaged with the research, ensuring that their needs are catered for, with the aim of tangibly benefitting from the interventions.
No expected impacts identified for this destination.
Regulation (EC) No 141/2000 of the European Parliament and of the Council on orphan medicinal products
highRegulation (EC) No 141/2000 sets out the EU framework to encourage the research, development, and marketing of orphan medicinal products for rare diseases affecting no more than 5 in 10,000 people in the EU. It establishes incentives such as protocol assistance, fee reductions for regulatory procedures, and a 10-year market exclusivity period upon marketing authorization.
Evaluators expect proposals targeting rare neurodegenerative disorders or specific orphan subpopulations to demonstrate a clear regulatory strategy aligned with this regulation. This includes outlining eligibility pathways for orphan designation through the European Medicines Agency (EMA), leveraging scientific advice/protocol assistance, and defining how clinical development milestones support eventual translation and market authorization under orphan drug provisions.
Nothing to show for this call yet.